thickness, and are characterized by specific endothelial-toparenchymal cellular interplays. Increasing evidence supports the notion of brain endothelial cells heterogeneity, characterized by variable patterns of gene and protein expression, tightness, and astrocytic coverage (Macdonald and others 2010) . This being said, the BBB is the most studied "segment" of the cerebrovasculature. The BBB is constituted by microcapillary endothelial cells enclosed in a perivascular basal lamina and astrocytic endfeet. Astrocytes constitute a bridge to neurons and parenchymal pericytes, the latter contributing to BBB functions. "The BBB supplies the brain with essential nutrients and mediates efflux of many waste products" (Abbott and others 2006) . The BBB was initially considered a static barrier to the passage of drugs or blood components into the brain, but is now recognized as a factor participating in the pathophysiology of several CNS disorders (Abbott and others 2010; Neuwelt and others 2011; Zlokovic 2008) . The BBB is a dynamic barrier with rheological (regulation of cerebral blood flow), transport (MDR), metabolic (P450), and immunological (leukocyte trafficking, adhesion molecules) aspects and functions. Moreover, and differently from neurons, BBB cells are not fixed in a post-mitotic state but rather react to various pathological and rheological signals to stimulate angiogenesis, leading to the formation of new microvessels and vascular remodeling (Abbott and others 2010; Bikfalvi 2006; Rigau and others 2007) .
A direct, causative link between BBB damage and seizures has been demonstrated clinically (Tomkins and others 2011) and experimentally (Marchi and others 2007; van Vliet and others 2007; Librizzi and others 2012) . BBB damage was observed in experimental models of seizures and in brain tissues resected from drug-resistant epileptic subjects. More recent evidence has demonstrated that BBB damage is part of a multifaceted, pathophysiological process affecting the "epileptic" cerebrovasculature. Specifically, a significant increase of vascular density in the hippocampus of patients suffering from drugrefractory temporal lobe epilepsy was reported (MorinBrureau and others 2011; Ndode-Ekane and others 2010; Rigau and others 2007) . The increased vascularization overlapped with the loss of tight junction proteins and leakage of serum proteins into the brain parenchyma (Michalak and others 2012; Rigau and others 2007; van Vliet and others 2007) .
The morphological changes observed in the epileptic foci suggested the occurrence of angiogenic processes. The latter was confirmed in temporal lobe epilepsy resection by high levels of vascular endothelial growth factor (VEGF) in neurons and astrocytes and by the overexpression of the receptor tyrosine kinase VEGFR-2 on BBB endothelial cells (Rigau and others 2007; see Figs. 1 and 2) . The VEGF/VEGFR-2 system functions according to different pathways. VEGF is a pleiotropic growth factor regulated by hypoxia or inflammation via transcription factors such as activator protein-1 (AP-1), hypoxia-inducible factor 1α (Hif α), specificity protein-1 (Sp-1), and signal transducer and activator of transcription 3 (STAT3). These transcription factors and VEGFR-2 are activated under pathological conditions, such as seizures (Bikfalvi 2006; Choi and others 2003; Feng and others 1997; Feng and others 1999; Gerber and others 1997; Kowanetz and Ferrara 2006; Meissner and others 2009; Pages and Pouyssegur 2005; Yancopoulos and others 2000) . In addition, the downstream signaling of VEGFR-2 controls vascular permeability and endothelial cell growth. Specifically, VEGFR-2 activates inositol trisphosphate (IP3), endothelial nitric oxide synthase (eNOS), and phospholipase C (PLC), allowing for proteolysis of the vascular basal membrane by matrix metalloproteinases, collagenase, heparinase, and plasminogen (Fig. 3) .
Comparable results were found in a rodent model of limbic epilepsy where the BBB was disrupted during epileptogenesis along with an increased microvascular density (Rigau and others 2007; Marcon and others 2009) . Furthermore, in vitro seizure-like events, as induced by kainic acid, triggered an angiogenic environment, namely the overexpression of VEGF in neurons and astrocytes and the overexpression of VEGFR-2 receptors in the endothelium and neurons. Similar to in vivo data, activation of VEGF-VEGFR-2 in vitro induced a significant increase of vascular density and tight junction disassembly. During seizures, VEGF is released to reach the BBB microvessels, interacting with endothelial receptor VEGFR-2 in a fashion similar to what is described for other CNS disease (Schiera and others 2007) . The role of the VEGF-VEGFR-2 system in BBB damage was confirmed using recombinant VEGF and an anti-VEGF drug (Morin-Brureau and others 2011; Rigau and others 2007) .
Targeting Cerebrovascular Remodeling in the Epileptic Brain
The recognition of cerebrovascular mechanisms of seizure has catalyzed the quest for new therapeutics aimed at reducing seizure burden. Novel drugs targeting the damaged BBB and angiogenesis could be used, alone or in combination with available anti-epileptic drugs (AEDs). Recent evidence has suggested that anti-inflammatory drugs targeting the leaky BBB exert anti-seizure effects. The blockade of BBB adhesion molecules or systemic pretreatment with glucocorticosteroids (GC) reduced seizure onset and burden in a rodent model (Fabene and others 2008; Fabene and others 2010; Marchi and others 2011a) . Remarkably, co-administration of GC and AEDs was effective in a cohort of drug-resistant epileptic children where infantile spasms, epileptic syndromes, and Rasmussen encephalopathy were excluded (Granata and others 2009 ).
More recent evidence has shown that targeting angiogenesis in the epileptic brain could be a viable approach to reduce seizures (Morin-Brureau and others 2011). Currently, anti-VEGF molecules are being tested for glioblastoma and age-related macular degeneration (Campa and Harding 2011) . The latter underscores that new antiangiogenic therapeutic approaches are clinically sound, granted adequate control of side effects. Supporting a role of angiogenesis in epilepsy, anti-VEGF antibody diminished vascularization and tight junction disassembly induced by kainic acid seizures in organotypic hippocampal culture (Morin-Brureau and others 2011). Although over-production of VEGF during seizures has detrimental effects on BBB permeability, VEGF was also demonstrated to contribute to neuron survival (Holmes and others 2007; Lee and others 2006; McCloskey and others 2005; Nicoletti and others 2008) . In particular, VEGFR-2 expressed by neurons directly provides an autocrine neuroprotection via the anti-apoptotic phosphatidylinositol 3-kinase PI3K pathway. Moreover, VEGFR-2 expressed by BBB endothelial cells was demonstrated to be involved in the neurovascular energetic coupling (Kowanetz and Ferrara 2006) . The VEGFR2 response follows two distinct pathways: Protein kinase C (PKC) activation, which induces endothelial cells proliferation and vascularization and eNOS activation, which further modulates the neurovascular interplay. Therefore, the beneficial effects of VEGFR-2 signaling on neuronal function should be taken into account when anti-angiogenic drugs are delivered to the CNS. One approach to control angiogenesis circumventing neuronal side effects could be targeting of the Src kinase pathway (Src). Src inhibition maintains or restores the BBB integrity, without affecting neuronal survival (Morin-Brureau and others 2011; Fig. 3 ). Other angiogenic factors can modify VEGF effects: Angiopoietins and their receptor Tie2 (tyrosine kinase with immunoglobulin and EGF homology domains) control vascular permeability and angiopoietin1 (Ang1) was shown to prevent the effects of VEGF on the vasculature (Gavard and others 2008) .
Angiogenesis, Inflammation, and Epilepsy: A Vicious Cycle
Despite evidence produced in the past years, a resilient debate takes place when attempting to establish a causative Irrespective of the fact that BBB damage (BBBD) precedes or results from seizures (blue circular arrows), vascular endothelial growth factor (VEGF) is released by neurons and glial cells (yellow dots) along with pro-inflammatory cytokines (m = microglial cells). VEGF acts on the VEGF-R2 receptors expressed on BBB endothelial cells increasing permeability, triggering angiogenesis, and vascular remodeling (see also Fig. 1 ). The formation of new, leaky BBB vessels is proposed to further promote seizures, reinforcing the vicious cycles (blue arrows). VEGF was also demonstrated to have neuroprotective effects (see also Fig. 3 ). Serum components (black dots) are free to penetrate into the brain in conditions of BBBD, altering the brain milieu and promoting seizures. Both brain (glial, microglial activation) and blood inflammation was shown to promote BBBD. A peripheral response encompasses blood leukocyte activation and interaction with the BBB (over-expression of chemokines and adhesion molecules) and the involvement of districts of immune competency (e.g., spleen, bone marrow). Under this condition, release of stress hormones, cytokines, and neurotransmitters into the peripheral blood could also alter BBB integrity and promote seizures.
role for BBB dysfunction in epilepsy (Friedman 2011; Fig. 2) . The question was and remains: Do seizures cause BBB dysfunction and remodeling or vice versa? Another great deal of controversy arises when trying to frame the etiological role of "brain-borne" and of "blood-borne" inflammation in determining BBB damage (Fabene and others 2008; Librizzi and others 2012; Marchi and others 2011b; Vezzani and others 2011b; Vezzani and others 2011a) . It is plausible to assume that, in the epileptic brain, a vicious cycle ensues where BBB dysfunction facilitates seizures and ongoing seizure activity exacerbates BBB damage and angiogenesis, further reiterating seizures (Fig. 2) . Moreover, regardless of the "source" of noxious pro-inflammatory signals, re-establishment of the proper BBB functions and impeding abnormal angiogenesis may be generally beneficial to reduce seizure burden. It is currently not clear whether a BBB mechanism of seizures plays a definite role in drug-resistant forms of epilepsy or whether BBB damage and remodeling is an epiphenomenon of seizures. The latter consideration is applicable to other non-neuronal events that were demonstrated to occur in response to seizures (e.g., activation of brain glial and microglial cells, leukocyte-BBB interaction; Fabene and others 2010; Vezzani and others 2011b). Moreover, it remains to be experimentally and clinically tested whether novel BBB drugs exert their maximum anti-seizure effects when administered in combination to AEDs (Marchi and others 2012) .
When considering possible clinical applications, the administration of anti-angiogenic molecules was proposed to be beneficial immediately after an ischemic stroke to avoid hemorrhagic transformation (Zhang and others 2000) . Anti-angiogenic therapy was also proposed for cases of aggressive brain tumors, where conventional therapies are ineffective to slow neoplastic growth. In the case of epileptic disorders, the paroxysmal nature of the disease may represent an additional challenge to by-pass. An anti-angiogenic therapy may need to be tailored for each patient based on AED responsiveness, seizure frequency, and severity in a manner similar to commonly prescribed AED. It is reasonable to hypothesize that interictal or pre-ictal regimens of anti-angiogenic drugs may be the most effective, preventing BBB leakage and seizures. However, these statements are premature, as this field of research has yet to benefit from a comprehensive evaluation of BBB status in relation to seizures characteristics and drug resistance.
Blood-Brain Barrier Remodeling and Neurovascular Dysplasia: A Common Etiological Factor in Drug-Resistant Forms of Epilepsy?
Drug-resistant forms of epilepsy are often accompanied with pathological brain substrates. In cases of symptomatic drug-resistant epilepsies, malformations of cortical development (MCD, (Shorvon 2011a (Shorvon , 2011b ; Spreafico and Blumcke 2010) represent a common etiological factor underlying seizures. Although aberrant neuronal circuitry was proposed to be the sole cause of hyperexcitability in the malformed brain areas, experimental evidence exists supporting the presence and role for ectopic BBB microvessels (Fan and others 2008; Hallene and others 2006; Marchi and others 2006) .
One of the most used models of MCD is based on the pre-natal exposure to methylazoxy-methanoic acid (MAM) in rats. MAM induces an ablation of periventricular neurons impeding their differentiation and migration to the developing cortex. The results include, in the adult rodent bran, cerebral heterotopias similar to those observed in humans (Colacitti and others 1998; Colacitti and others 1999) such as ectopic neurons in the periventricular and hippocampal regions and cortical thinning. Accompanying neuronal ectopias is the loss of radial cortical vessels. In addition, BBB microvessels have a tortuous morphology and are leaky to fluorescent tracers (Marchi and others 2006) . MAM rats have a lower seizure threshold and seizures elicited in the MAM brain are associated with a greater extent of BBB leakage compared with seizures induced in naïve animals (Chevassus-Au-Louis and others 1998; Chevassus-Au-Louis and others 1999; Tschuluun and others 2011). The fact that the BBB of MAM is intrinsically leaky may contribute to a lower seizure threshold, tilting the blood-brain parenchyma homeostatic equilibrium toward a pro-seizure state. Furthermore, the greater extent of BBB damage observed in response to seizures could reiterate seizures in a fashion that is more severe compared to naïve brains. What remains unclear is the mechanism underlying BBB dysfunction in MCD and the exact role of angiogenesis. Using naïve, non-MCD rodents, recent evidence has proposed a role for the VEGF/ VEGR-2 pathway in determining BBB leakage during seizures. Whether a similar mechanism applies to the dysplastic BBB is unknown. This could be of direct clinical relevance owing the fact the MCD is often associated with refractory seizures and it is problematic, using only human tissues, to dissociate the importance of inborn BBB lesions from the effects triggered by seizure activity.
Blood-Brain Barrier Remodeling and the Role of Pericytes
Apart from glial and endothelial cells, pericytes also contribute to BBB physiology and integrity (Winkler and others 2011; Zlokovic 2008 ; Fig. 1 ). Pericytes are located in the perivascular space of the BBB surrounding the endothelial cells to which they are connected via integrin molecules, connexin 43, and N-cadherin. The function of pericytes was recently reviewed in Winkler and others (2011) . In general, pericytes are involved in the maintenance of proper BBB properties and architecture such as the expression and distribution of tight junction proteins, vascular stability, diameter, and blood flow. Studies conducted using mutant mice demonstrated that pericytes deficiency leads to a leaky BBB (Armulik and others 2010; Armulik and others 2011) and that pericytes are required for proper brain angiogenesis (Daneman and others 2010) . As pericytes are anatomically placed between endothelial and glial cells, their deficiency could affect both glial and endothelium functions. Evidence exists for a role of pericytes in controlling potassium inward rectifier (Kir 4.1) and aquaporins (AQ-4) expression, also regulating brain homeostasis (Armulik and others 2010) .
Diminished pericyte BBB coverage is a pathological event observed in a variety of brain diseases associated with cerebrovascular instability and neurodegeneration (Winkler and others 2011) . Recent data have shown that ischemia induces pericyte dysfunction. Capillary constriction after acute stroke was determined by pericyte contraction, reducing cerebral blood flow (Yemisci and others 2009) . Although no concrete evidence is available yet on the role of pericytes in the epileptic brain, a few clues suggest that, in cases of malformation of cortical development, pericyte BBB coverage may be altered (Daneman and others 2010) . The latter may represent a mechanism contributing to the formation of ectopic BBB capillaries in malformed brain areas. Whether seizures per se alter pericytes function and BBB coverage remains to be fully elucidated (Fig. 1) .
Does Blood-Brain Barrier Remodeling Influence Brain Autoregulation and Drug Penetration?
The brain autoregulates itself, maintaining an optimal cerebral blood flow despite changes in arterial perfusion pressure. Loss of brain autoregulation is associated with several CNS diseases, resulting in an incapability of balancing between CNS metabolic demand and blood oxygen supply. Cerebral perfusion is regulated by different mechanisms depending on vessel location (subcortical vs. parenchymal), type (venous vs. arterial), innervations, and caliber. Whereas at the level of subcortical vessels, the release of neurotransmitters on endothelial or smooth muscle cells plays a major role, in the case of parenchymal microvessels, glial cells were demonstrated to influence vascular tone (Gordon and others 2007; Gordon and others 2008) .
In seizure disorders, the sudden and repetitive changes in metabolic demand occurring during inter-ictal to ictal transitions may challenge the cerebral autoregulatory mechanism. The existence of pathologically remodeled, leaky BBB microvessels may also interfere with the autoregulatory signals coming from the upstream cerebral vessels. Formation of brain edema could be facilitated and exacerbated by the concomitance of leaky BBB vessels and deviation from optimal autoregulatory conditions. Cerebrovascular integrity and tonicity is also regulated by intravascular pressure forces. Specifically, the oncotic pressure exerted by plasma proteins impedes fluid to leak out of the BBB capillaries. The combination of the intra-vascular oncotic forces and hydrostatic pressure, together with the tightness of the BBB endothelium, prevents the formation of vasogenic edema. What remains to be elucidated is whether this symmetry of pressures and concentration gradients is maintained in the epileptic, remodeled BBB microvessels (Janigro 2012) . Moreover, loss of BBB tightness, brain edema, and passage of serum proteins into the brain parenchyma could affect the kinetics of drug penetration into the epileptic brain. Whereas significant effort has been devoted to investigating whether BBB multi-drug transporter proteins impede entry of AEDs into the epileptic brain, the fact that the epileptic BBB is leaky has been somehow overlooked. In the case of tight junction loss, or increased BBB permeability in general, extravasation of serum proteins into the brain may reduce the availability of free drug in a fashion that depends on drug lipophilicity (Kimelberg 2004) . Bearing in mind that only a few micrometers separate BBB vessels from neurons, it is reasonable to hypothesize that a remodeled leaky BBB, allowing for plasma protein to penetrate into the brain, could influence the brain availability of AED. Restoring BBB integrity could reestablish the optimal blood-to-brain separation and AED distribution, ultimately improving therapeutic effects.
Conclusions
The discovery that vascular remodeling and angiogenesis occur in the epileptic brain further strengthens the concept that epilepsy shares pathological tracts with other CNS diseases. Based on available evidence, BBB damage and angiogenesis can be considered the common endpoint of pathological stimuli initiated in the brain or in the periphery. This opens a great opportunity for new therapeutic interventions, where drugs used for other brain disease could be "borrowed" in the attempt to treat seizures. Whether vascular remodeling and leaky BBB are specific features of drug-resistant forms of seizures remains to be elucidated. It remains to be determined whether targeting aberrant angiogenesis and leaky BBB vessels could constitute a valid approach to improve seizure control in drug-resistant epilepsy. Whether antiangiogenic drugs should be administered in combination with AEDs remains to be clarified. Nevertheless, the discovery of common inter-disease features is allowing the field of epilepsy research to move forward, expanding the understanding of this disease.
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